- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04306952
Awareness and Self-Compassion Enhancing Narcolepsy Treatment (ASCENT)
October 9, 2023 updated by: Jennifer Mundt, PhD, Northwestern University
Mind-Body Approach to Improve Health-Related Quality of Life for People With Narcolepsy
The overall goal of this research is to test the effectiveness of a mindfulness-based intervention (MBI) for improving health-related quality of life as a complementary practice to standard care for narcolepsy.
This study is a feasibility trial in which 60 adults with narcolepsy will be randomized to receive either a 4-week (brief), 8-week (standard), or 12-week (extended) MBI.
Each MBI will be delivered in small groups using a live videoconferencing platform and teaches mindfulness practices to help cope with narcolepsy symptoms.
By developing a scalable mind-body intervention, this project can addresses a major research gap on improving psychosocial functioning in people with narcolepsy.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Narcolepsy is a serious and debilitating condition involving persistent and excessive sleepiness that affects 1 in 2000 Americans and 3 million people worldwide.
Although wake-promoting pharmacotherapy can reduce sleepiness there is no cure and people with narcolepsy experience significantly poor health-related quality of life, particularly in the domains of mental and social health.
Therefore, the overarching goal of this research is to test the effectiveness of a mindfulness-based intervention (MBI) for improving health-related quality of life as a complementary practice to standard care for narcolepsy.
The purpose of this study is to conduct a feasibility trial to determine the optimal parameters for adapting and delivering MBI to people with narcolepsy.
The specific aims are to: 1) Determine the feasibility and acceptability of MBI delivered using videoconferencing for the purpose of improving psychosocial functioning in people with narcolepsy and 2) Determine the feasibility of recruitment and assessment methods for delivering MBI using videoconferencing.
The feasibility trial includes 60 adults with narcolepsy who will be randomized to receive either a 4-week (brief), 8-week (standard), or 12-week (extended) MBI.
Each MBI will be similar in content, which includes mindfulness practices and group discussions with adaptations for working with narcolepsy symptoms.
All MBIs will be delivered in small groups using a live videoconferencing platform to enhance accessibility.
If the findings of this project support the feasibility of further testing, the next project would be aimed at enhancing rigor and reproducibility (e.g., designing appropriate control, refining outcome measures and eligibility criteria) in preparation for a large-scale pragmatic trial.
The overall significance of this research is to develop a scalable mind-body intervention that addresses a major research gap on improving psychosocial functioning in people with narcolepsy.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Center for Circadian and Sleep Medicine, Northwestern University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Males and females age 18 and older (except when the age of majority for a state differs from 18, including Delaware [19 years or older], Mississippi [21 years or older], and Nebraska [19 years or older])
- ICSD-3 criteria (8) for Narcolepsy (Type I or II)
- Endorse current psychological distress based on a t-score ≥ 60 on the PROMIS depression or anxiety scales
- Established standard care for narcolepsy. Patients who have not been previously diagnosed will be required to complete a clinical work-up through a sleep clinic (i.e., nocturnal PSG followed by a next-day MSLT) before participating. Standard care is managed outside of the study.
Exclusion Criteria:
- Hypersomnia not of central origin (i.e., hypersomnia attributed to psychiatric disorder, medical disorder, other sleep disorder such as circadian rhythm sleep disorder, or insufficient sleep).
- Current suicidal ideation or intent.
- Uncontrolled medical conditions or physical limitations that require immediate medical treatment that would prevent ability to engage in the treatment protocol.
- Inability to engage in the treatment protocol due to a psychiatric (e.g., psychotic disorder) or cognitive issue.
- Untreated moderate-to-severe sleep-related breathing disorder, defined as an apnea hypopnea index (AHI) ≥ 15. Those receiving treatment for a sleep-related breathing disorder and can demonstrate adequate management (e.g., residual AHI < 5) will be allowed to participate.
- Previous participation in a formal MBI program, such as MBSR.
- Unstable dose of medications at the time of screening (e.g., stimulants).
- Unable to attend intervention sessions due to accessibility (i.e., reliable internet connection) or availability (i.e., not available due to scheduling conflicts).
- Currently living outside of the United States.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Brief MBI
The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat.
|
The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat.
The rationale for testing the short MBI is to evaluate a low-dose (8 hours of contact) MBI that optimizes cost-effectiveness and minimizes patient burden.
|
Experimental: Standard MBI
The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat.
|
The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat.
The length of this package is based on the standard length of MBSR as an 8-week program.
The rationale for testing the standard MBI is to provide a comparison to a dose (16 hours of contact) that is most similar to the length of MBSR and has the fewest modifications, making it easier to train MBI providers.
|
Experimental: Extended MBI
The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks, with optional "office hours"in between the bi-weekly group sessions and one all day meditation retreat.
|
The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks.
Each group session will be two hours.
The group sessions will be identical to the standard package except for the timing (every other week) of the last four sessions.
In addition to the group sessions, the MBI provider will offer "office hours" in between the bi-weekly group sessions, where participants will be able to schedule individual sessions with the MBI provider to discuss questions and troubleshoot their mindfulness practice.
In addition, participants will receive an all-day meditation retreat, similar to the other conditions.
The rationale for testing the extended MBI is to optimize acceptability and uptake based on the investigator's preliminary data by allowing for a slower, extended pace of learning mindfulness practices with an opportunity to have individual discussions with the instructor (16 hours of contact + individual office hours).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Attended ≥ 80% of Sessions
Time Frame: 4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI)
|
Number of participants who attended greater than or equal to 80% of sessions
|
4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI)
|
Number of Participants Who Practiced Meditation ≥ 4 Days Per Week
Time Frame: 4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI)
|
Number of participants who practiced meditation greater than or equal to 4 days per week
|
4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI)
|
Number of Participants Who Completed Assessments
Time Frame: Baseline and 4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI)
|
Number of participants who completed entire baseline and post-treatment assessment (questionnaires, actigraphy, and neurocognitive testing)
|
Baseline and 4 weeks (Brief MBI), 8 weeks (Standard MBI), or 12 weeks (Extended MBI)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-Compassion Scale (SCS)
Time Frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
|
The SCS assesses the acquisition of self-compassion.
It is a 26-item self report measure with three main components of self-compassion: self-kindness vs. self-judgement, common humanity vs. isolation, and mindfulness vs. over-identification.
The total score ranges from 1-5, with higher scores reflecting more self-compassion.
|
Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
|
Five Facet Mindfulness Questionnaire (FFMQ)
Time Frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
|
The FFMQ assesses the acquisition of mindfulness skills.
It is a 39-item self-report measure that consists of five factors representing elements of mindfulness: observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience.
Total scores range from 39-195, with higher scores reflecting more mindfulness.
|
Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
|
Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Positive
Time Frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
|
Measures the direct positive psychosocial effect related to illness with higher scores reflecting better outcomes.
Population mean (T-score) of 50 with a standard deviation of 10.
|
Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
|
Patient Reported Outcomes Measurement Information System (PROMIS) Psychosocial Illness Impact Negative Scale
Time Frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
|
Measures the direct negative psychosocial effect related to illness with higher scores reflecting worse outcomes.
Population mean (T-score) of 50 with a standard deviation of 10.
|
Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
|
Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale
Time Frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
|
Measures overall physical and mental health with higher scores reflecting better outcomes.
Population mean (T-score) of 50 with a standard deviation of 10.
|
Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
|
Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale
Time Frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
|
Measures anxiety symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more anxiety symptoms (worse outcome).
Population mean (T-score) of 50 with a standard deviation of 10.
|
Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
|
Patient Reported Outcomes Measurement Information System (PROMIS) Depression Scale
Time Frame: Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
|
Measures depressive symptoms using Computer Adaptive Testing (CAT) with higher scores reflecting more depressive symptoms (worse outcome).
Population mean (T-score) of 50 with a standard deviation of 10.
|
Baseline to post-treatment (Brief MBI 4 weeks, Standard MBI 8 weeks, Extended MBI 12 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jennifer Mundt, PhD, Northwestern University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 15, 2020
Primary Completion (Actual)
May 30, 2022
Study Completion (Actual)
June 30, 2022
Study Registration Dates
First Submitted
February 28, 2020
First Submitted That Met QC Criteria
March 10, 2020
First Posted (Actual)
March 13, 2020
Study Record Updates
Last Update Posted (Actual)
November 1, 2023
Last Update Submitted That Met QC Criteria
October 9, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU00209890
- R34AT009551 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Narcolepsy
-
University of Dublin, Trinity CollegeSt. James's Hospital, IrelandSuspendedNarcolepsy | Hypersomnolence | Narcolepsy Type 1 | Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy | Narcolepsy 1 | Narcolepsy and HypersomniaIreland
-
Northwestern UniversityActive, not recruitingNarcolepsy | Narcolepsy Type 1 | Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy | Narcolepsy Type 2United States
-
NLS PharmaceuticsCompletedNarcolepsy | Narcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
-
Boston Children's HospitalAmerican Academy of Sleep MedicineRecruitingIdiopathic Hypersomnia | Narcolepsy Type 1 | Narcolepsy Type 2United States
-
NLS PharmaceuticsNot yet recruitingNarcolepsy Type 1 | Narcolepsy With Cataplexy
-
TakedaRecruitingNarcolepsy Type 1 | Narcolepsy Type 2Spain, Germany, United States, Italy, Netherlands, Japan, France, Norway, Australia, Finland, Switzerland, Sweden
-
BioprojetActive, not recruitingNarcolepsy Without Cataplexy | Narcolepsy With CataplexyFrance, Italy, Russian Federation, Finland, Netherlands
-
TakedaTerminatedNarcolepsy Type 1 (NT1) | Narcolepsy Type 2 (NT2)China, United States, Korea, Republic of, France, Italy, Finland, Spain, Czechia, Canada, Japan, Hungary, Netherlands
-
Emory UniversityNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingIdiopathic Hypersomnia | Narcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
-
Harmony Biosciences, LLCNo longer availableNarcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
Clinical Trials on Brief MBI
-
Piazza della Vittoria 14 Studio Medico - Ginecologia...CompletedCOVID | Post Traumatic Stress DisorderItaly
-
City, University of LondonCompletedParkinson's DiseaseUnited Kingdom
-
Sunnybrook Health Sciences CentreCompletedDepression | Anxiety | Mood
-
ARCIM Institute Academic Research in Complementary...Harvard Medical School (HMS and HSDM); Universität TübingenCompletedStress, Psychological
-
Carnegie Mellon UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Recruiting
-
Karl Landsteiner Institute for Lung Research and...Klinik Ottakring; University of Vienna; Klinik Floridsdorf; Therme Wien Med (Ambulant...CompletedChronic Obstructive Pulmonary Disease ExacerbationAustria
-
Vanderbilt University Medical CenterTerminatedDepression | Stress | Major Depressive DisorderUnited States
-
Vanderbilt University Medical CenterCompletedChronic Pain | Pain, Chronic | Pain, Intractable | Pain Syndrome | Pain, NeuropathicUnited States
-
Göteborg UniversitySahlgrenska University Hospital, SwedenCompleted
-
University of PaviaUniversità degli Studi di BresciaCompleted